deltatrials
Unknown OBSERVATIONAL NCT04328818

Indwelling Device-associated Biofilms (BiofilmICU)

Indwelling Device-associated Biofilms in Oncological Critically Ill Patients

Sponsor: Grigore T. Popa University of Medicine and Pharmacy

Updated 13 times since 2020 Last updated: Mar 14, 2022 Started: Jun 5, 2019 Primary completion: Sep 5, 2023 Completion: Oct 5, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Critical Illness and Hospital Infection, this trial is ongoing. The trial is conducted by Grigore T. Popa University of Medicine and Pharmacy and has accumulated 13 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Study Description(click to expand)

According to Regional Institute of Oncology, Iasi protocols, all septic patients with the need of invasive ventilatory support (endotracheal intubation), have concomitantly inserted a CVC, an AC and a UC, as standard of care. All patients undergo the protocol for the management of suspected/proven sepsis: initial resuscitation, specimen collection for microbiology/molecular biology tests, empirical/targeted anti-infectious treatment, source control, multiple organ support and treatment of the underlying disease/comorbidities. All RIO patients are screened for nasal, pharyngeal and rectal pathogen colonization at the time of hospital/ICU admission. Informed consent - During the first 24 hours of ICU admission, all eligible patients will receive written information about the study: its implementation, aims, expected advantages and possible risks, and they will be asked to sign an informed consent. If the patient is unable to give consent at ICU admission due to pathological or drug-induced acute alteration of consciousness, a legal representative may give authorization. Once the participant regains the decision capacity, the individual will be asked to confirm or withdraw consent. Swab sampling - The nasal, pharyngeal and rectal screening swab sampling is collected according to standard methods. In addition to this standard screening, in the first 24 hours of ICU admission cutaneous samples...

According to Regional Institute of Oncology, Iasi protocols, all septic patients with the need of invasive ventilatory support (endotracheal intubation), have concomitantly inserted a CVC, an AC and a UC, as standard of care. All patients undergo the protocol for the management of suspected/proven sepsis: initial resuscitation, specimen collection for microbiology/molecular biology tests, empirical/targeted anti-infectious treatment, source control, multiple organ support and treatment of the underlying disease/comorbidities. All RIO patients are screened for nasal, pharyngeal and rectal pathogen colonization at the time of hospital/ICU admission.

Informed consent - During the first 24 hours of ICU admission, all eligible patients will receive written information about the study: its implementation, aims, expected advantages and possible risks, and they will be asked to sign an informed consent. If the patient is unable to give consent at ICU admission due to pathological or drug-induced acute alteration of consciousness, a legal representative may give authorization. Once the participant regains the decision capacity, the individual will be asked to confirm or withdraw consent.

Swab sampling - The nasal, pharyngeal and rectal screening swab sampling is collected according to standard methods. In addition to this standard screening, in the first 24 hours of ICU admission cutaneous samples from the groin area of enrolled patients will be obtained, with sterile Copan eSwabTM swabs, a product recommended for aerobic, anaerobic and fastidious microbial agents.

Biofilm sampling and transport - The extraction of the four ID (ET, CVC, AC, UC) will be performed when the clinical condition of the patient dictates it (suspected catheter infection/no further need due to improvement or death). These devices will be extracted by medical ICU personnel, only at the indication and according to the medical judgment of the clinician, without being influenced by the patient's study participation.

Microbiological processing and analysis of the biofilm - Microbiological analysis will be performed by standard method: sample seeding on standard culture media, then biochemical identification test and AST according to CLSI standards and guidelines using MicroScan Walk Away 40 plus®, Beckmann Coulter automatic system compatible pannels.

Molecular biology processing and analysis of the biofilm - After complete sample collection, gene sequencing of the variable regions V3-V4 16S rRNA gene will be performed using Illumina MiSeq® Next Generation Sequencer System.

Status Flow

~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Nov 2020 · 4 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Apr 2022 · 4 months · monthly snapshot~Apr 2022 – ~Jul 2024 · 27 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Nov 2025 · 2 months · monthly snapshot~Nov 2025 – present · 5 months · monthly snapshot~Jan 2026 – present · 3 months · monthly snapshot

Change History

13 versions recorded
  1. Jan 2026 — Present [monthly]

    Unknown

  2. Nov 2025 — Present [monthly]

    Unknown

    Status: Active Not RecruitingUnknown

  3. Sep 2025 — Nov 2025 [monthly]

    Active Not Recruiting

  4. Sep 2024 — Sep 2025 [monthly]

    Active Not Recruiting

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting

Show 8 earlier versions
  1. Apr 2022 — Jul 2024 [monthly]

    Active Not Recruiting

  2. Dec 2021 — Apr 2022 [monthly]

    Active Not Recruiting

  3. Jan 2021 — Dec 2021 [monthly]

    Active Not Recruiting

  4. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting

  5. Jul 2020 — Nov 2020 [monthly]

    Active Not Recruiting

  6. Jun 2020 — Jul 2020 [monthly]

    Active Not Recruiting

  7. May 2020 — Jun 2020 [monthly]

    Active Not Recruiting

    Status: SuspendedActive Not Recruiting

  8. Apr 2020 — May 2020 [monthly]

    Suspended

    First recorded

Jun 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Grigore T. Popa University of Medicine and Pharmacy
Data source: Grigore T. Popa University of Medicine and Pharmacy

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations